Long Day Wear Experience with Water Surface Daily Disposable Contact Lenses

Abstract

Objective

The purpose of this study was to assess the wear experience of silicone hydrogel daily disposable contact lenses with water surface technology over a long day of lens wear.

Methods

Thirty-five soft contact lens wearers were refit with the daily disposable study lenses and participants scored their initial impressions of comfort, vision and satisfaction using a visual analog scale (VAS). Participants used their smart phones to complete surveys of comfort and vision on a scale of 1–10 at 10, 12, 14, and 16 hours of lens wear on 5 weeknights. A participant score for each time point was calculated by averaging the evening responses. End of study VAS surveys of symptoms were also completed.

Results

Median (Interquartile Range) VAS initial impression scores were 99.00 (12.00) for quality of vision, 98.00 (16.00) for comfort, and 100.00 (13.00) for satisfaction. The end of study surveys found end of day median VAS scores of 87.00 (19.00) for end of day quality of vision and 75.00 (24.50) for end of day comfort. The median score for overall quality of vision was 93.00 (14.00) and for overall comfort was 93.00 (16.50). The median score for end of day dryness was 37.00 (55.00) and overall dryness was 13.00 (34.00).

Conclusion

The daily disposable lenses with water surface treatment used in this study maintained high median scores for comfort and quality of vision for up to 16 hours of wear.

Keywords:

• daily disposable contact lenses
• water surface contact lenses
• comfort
• end of day comfort
• long wear time

Data Sharing Statement

Data reported in this manuscript are available within the article. Study-level data including the study protocol are available. To request access to the data, the researcher must sign a data use agreement. All proposals should be directed to [email protected] for up to 36 months following article publication.

Acknowledgments

Funding for this investigator initiated trial was provided by Alcon, Inc., Fort Worth, TX, USA. The project described was supported in part by Award Number Grant UL1TR002733 from the National Center for Advancing Translational Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.

Disclosure

Dr Jennifer Swingle Fogt reports grants from Alcon, Inc, during the conduct of the study; grants and/or personal fees from Alcon, Eyenovia, Nevakar, Unicon, Contamac, Innovega, and Bausch + Lomb, outside the submitted work. The authors report no other conflicts of interest in this work.